10 May, 2019
Last year was strong for IPOs in the biotechnology sector, with the amount of capital raised increasing, despite a lower volume of IPOs.
Baker McKenzie’s Ben McLaughlin, Ashok Lalwani and Adam Farlow discuss the factors driving these trends and consider what lies ahead for the sector, including the rationale for a healthcare company considering an IPO, the key business attributes of an IPO-ready healthcare company, the choice of listing venue, and the key issues such a company will need to consider before going public.
Please click here to read the pdf of the article.
For further information, please contact:
Ben McLaughlin, Partner, Baker & McKenzie
Ben.McLaughlin@bakermckenzie.com
